Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Neoadjuvant HER2+
Brain Cancer
Bone Metastases
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Precision Medicine in Oncology
®
Sarcomas
Special Reports in Personalized Cancer Care
Supportive Care
Urologic Oncology
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Neoadjuvant HER2+
More >>
2018 ASCO Annual Meeting
<< View Full Coverage
Oncology Conference Multimedia
Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC
Dr. Tewari on the Promise of Immunotherapy in Cervical Cancer
Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL
Dr. Iwata Discusses DS-8201a in HER2+ Breast Cancer
Dr. Link on Nelarabine in Newly Diagnosed T-Cell Malignancies
Dr. Richardson on the Synergy Between Immunomodulators and Proteasome Inhibitors
Dr. Upadhyaya on Radiation Therapy for Young Children with Ependymoma
Dr. Mok on Dacomitinib for First-Line Lung Cancer Treatment
Dr. Maughan on Enzalutamide Plus Radium-223 in mCRPC
Dr. El-Deiry on Liquid Vs Tissue Biopsies
Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell Lymphoma
Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC
Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer
Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC
Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma
Dr. Chari on the Subgroup Analysis of MMY1001 in Multiple Myeloma
Dr. Dimopoulos on Ibrutinib/Rituximab Treatment for Waldenstrom Macroglobulinemia
Dr. Kolberg Explains the Approval Process for Biosimilars
Dr. Rosenberg Discusses Enfortumab Vedotin in Urothelial Carcinoma
Dr. Garon Discusses Pegilodecakin Plus a PD-1 Inhibitor in NSCLC
Dr. Kreitman on Results of Moxetumomab Pasudotox in Hairy Cell Leukemia
Dr. Schwark on Microsatellite Instability and Lynch Syndrome
Dr. Pennell on the Economic Impact of Next-Generation Sequencing
Dr. Katzel on Women Being Undertreated for Head and Neck Cancer
Dr. Hong on Advances in Head and Neck Cancer
Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer
Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC
Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma
Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma
Dr. Ascierto on the COLUMBUS Trial in Melanoma
Dr. Kolberg Discusses the Central Pathology Review of ABP 980
Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC
Dr. Zibelman on Managing Immune-Related Adverse Events
Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC
Dr. Drake Discusses the CARMENA Trial in Metastatic RCC
Dr. McBride Discusses Financial Toxicity in Oncology
Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma
Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC
Dr. Tewari on Trial With Cemiplimab in Recurrent or Metastatic Cervical Cancer
Dr. Wang Discusses the ZUMA-2 Trial in Mantle Cell Lymphoma
Dr. O'Malley on the FORWARD II Phase Ib Study in Ovarian Cancer
Dr. Dent Discusses the LOTUS Trial in Triple-Negative Breast Cancer
Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma
Dr. Rini Discusses the Findings of IMmotion151 in RCC
Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL
Dr. Halabi Discusses Overall Survival Between African-American and Caucasian Men With mCRPC
Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas
Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell Lymphoma
Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC
Dr. Conroy Discusses Adjuvant mFOLFIRINOX in Pancreatic Cancer
Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell Carcinoma
OncLive News Network On Location: In Chicago Monday, June 4
Dr. Lopes on the KEYNOTE-042 Results of Frontline Pembrolizumab in NSCLC
Dr. Drilon Discusses Efficacy Results With LOXO-292 in RET-Altered Solid Tumors
OncLive News Network On Location: In Chicago Sunday, June 3
Dr. Jotte on the IMpower131 Findings in Squamous NSCLC
Dr. Slamon on the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer
OncLive News Network On Location: In Chicago Saturday, June 2
Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study
Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma
OncLive News Network On Location: In Chicago Friday, June 1
Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer
Dr. George on Results of Abi Race Trial in Prostate Cancer
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Trending Now
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
Targeting BCL-2 in Hematologic Malignancies
Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x